Mr. Dhillon is the CEO and Chair of Skye Bioscience (OTCQB: SKYE), a biopharmaceutical company focused on unlocking the pharmaceutical value of cannabinoids. Prior to Skye, Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. During his tenure at OncoSec, he oversaw and completed a partnership with Merck to launch Keynote 695, a phase II/III global multi-center registration clinical study of late-stage metastatic melanoma, raised over $200 million, and listed the company on NASDAQ. His experience spans corporate finance, M&A, integration, successful in-licensing of key intellectual property, strategy implementation, international corporate transactions, and collaborations with leading universities and key opinion leaders. He also serves on the board of directors of other life science companies and acts as an advisor and consultant in several capacities to different life science organizations. He is the creator of Torpedo Publishing, a publishing imprint serving to connect, inspire, and educate future game changers looking to positively impact the world.